About
Technology
Issues
FAQ
Search
Profile
Top Authors
Prolific Authors
Top Journals
Main Disciplines
Main Topics
Most Cited Articles
Scientometrics
Avg Impact Factor
★★
Articles
★★★
Articles
Citing Bodies
Top Citing Authors
Top Citing Institutions
Top Citing Schools
Top Citing Journals
Top Citing Disciplines
exaly
›
Schools
›
Division of Hematology/Oncology
›
top-articles
Division of Hematology/Oncology
17
(top 2%)
papers
287
(top 5%)
citations
10
(top 2%)
h
-index
18
(top 2%)
g
-index
19
all documents
302
doc citations
191
citing journals
Top Articles
#
Title
Journal
Year
Citations
1
Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer
BMC Cancer
2011
84
2
Drug-Metabolizing Enzyme Polymorphisms Predict Clinical Outcome in a Node-Positive Breast Cancer Cohort
Journal of Clinical Oncology
2005
47
3
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up
Annals of Oncology
2023
24
4
Clinicopathogenomic analysis of mismatch repair proficient colorectal adenocarcinoma uncovers novel prognostic subgroups with differing patterns of genetic evolution
International Journal of Cancer
2016
23
5
PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
Clinical Advances in Hematology and Oncology
2015
20
6
Designing CAR T cells for glioblastoma
OncoImmunology
2015
18
7
Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer
The Journal of Targeted Therapies in Cancer
2018
16
8
Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer
Expert Opinion on Drug Metabolism and Toxicology
2015
14
9
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design
Oncologist
2017
11
10
Using Benchmarks Based on Historical Survival Rates for Screening New Therapies for Stage IV Melanoma Patients
Journal of Clinical Oncology
2008
10
11
Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)
Annals of Oncology
2019
9
12
Identifying Professional Education Gaps and Barriers in Multiple Myeloma Patient Care: Findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee
Clinical Lymphoma, Myeloma and Leukemia
2014
7
13
HER2 imaging in the ZEPHIR study
Annals of Oncology
2016
7
14
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Journal of Visualized Experiments
2016
5
15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Journal of Visualized Experiments
2016
3
16
Chimeric Antigen Receptor T Cells in Chronic Lymphocytic Leukemia
Cancer Journal (Sudbury, Mass )
2019
2
17
Paired specimens
Cancer
2010
1
18
Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens
American Journal of Hematology
2013
1
19
1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study
Annals of Oncology
2022
0
site/software ©
exaly
; All materials licenced under
CC by-SA
.